Schizophrenia Prodrome

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Schizophrenia Prodrome trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingNot Applicable

NCT05142735

Effects of NAC on Symptoms of CHR Patients

Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia…

Canada90 participantsStarted 2023-01-13

Treatment: N-Acetylcysteine, Placebo

RecruitingPhase 2

NCT05052853

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhan…

Taiwan48 participantsStarted 2021-11-01

Treatment: NMDAE, Placebo Cap

All recent trials (24 shown)

CompletedPhase 3

NCT02751632

The Staged Treatment in Early Psychosis Study

A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patien…

Australia342 participantsStarted 2016-04

Treatment: Support and Problem Solving Therapy, Cognitive Behavioural Case Management

CompletedPhase 2

NCT00635700

Ziprasidone in the Psychosis Prodrome

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

United States51 participantsStarted 2008-03

Treatment: ziprasidone, placebo

Schizophrenia Prodrome

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

Effects of NAC on Symptoms of CHR Patients

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

All recent trials (24 shown)

The Staged Treatment in Early Psychosis Study

Ziprasidone in the Psychosis Prodrome

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

Effects of NAC on Symptoms of CHR Patients

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

All recent trials (24 shown)

The Staged Treatment in Early Psychosis Study

Ziprasidone in the Psychosis Prodrome

Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis

"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"

Brain Imaging in Early Psychosis

Glycine vs Placebo for the Schizophrenia Prodrome

Effects of Neurocognitive and Social Cognitive Remediation in Patients at Ultra-High Risk of Psychosis

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis

Computer-Aided Learning for Managing Stress

D-serine for the Schizophrenia Prodrome

Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis

Aripiprazole Treatment of Prodromal Patients

Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia

Ethyl-EPA Treatment of Prodromal Patients

Indicated Prevention of Psychotic Disorders With Low-dose Lithium

Aripiprazole Treatment of the Prodrome

Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia

Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia

Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis